Tarina Fe 1 / 20 is a monophasic microdose contraceptive intended for birth control by preventing an unwanted pregnancy.
Contents:
Indications for use
Tarina Fe 1 / 20 is a means for birth control. The therapy of moderate acne and severe premenstrual syndrome may be also carried out by means of this medication.
Mechanism of action
Tarina Fe 1 / 20 is a kind of combined hormonal birth control possessing anti-aldosterone and anti-androgenic effects. The contraceptive effect is maintained on the background of different aspects, the most significant of which is the suppression of ovulation. It also contributes to the changes in the viscosity of cervical secretions. Finally, it becomes rather difficult for spermatozoa to get through the uterine cavity.
Mode of application and dosage
Tarina Fe 1 / 20 contains 28 pills 7 of which contains no hormone. The course duration is 28 pills. The regimen includes daily basis. The pill is taken at one and the same time. When a woman takes 7 placebo pills the menstruation will start.
Contraindications
Tarina Fe 1 / 20 has a number of contraindications which should be taken into account before starting taking this birth control drug. They include the following medical conditions:
- high risk of venous or arterial thrombosis;
- venous and arterial thrombosis and thromboembolism, cerebrovascular disorders;
- conditions preceding thrombosis: currently diagnosed or found in the medical history;
- diabetes with vascular complications;
- migraine with focal neurological symptoms now or in history;
- liver failure and severe liver disease (until normalization of liver function indicators);
- liver tumors (benign or malignant) now or in history;
- severe renal failure, acute renal failure;
- adrenal insufficiency;
- vaginal bleeding of unspecified etiology;
- pregnancy or breastfeeding;
- hypersensitivity to any of the components of the drug;
- lactose intolerance, lactase deficiency, glucose-galactose malabsorption (lactose monohydrate is included in the preparation).
Side effects
Body systems | Often met | Infrequently met | Rarely met | Unknown frequency |
infectious and parasitic diseases | – | vaginitis/vulvovaginitis, vaginal candidiasis or other fungal vulvovaginal infections |
salpingo-oophoritis (adnexitis), urinary tract infections, cystitis, mastitis, cervicitis, fungal infections, candidiasis, herpetic oral cavity disease, influenza, bronchitis, sinusitis, upper respiratory infections, viral infection. | – |
benign, malignant and unspecified neoplasms (including cysts and polyps) | – | – | uterine fibroids, breast lipoma. | – |
hematopoietic system | – | – | anemia | – |
immune system | – | – | allergic reactions | – |
endocrine system | – | – | virilism | – |
metabolism and nutrition | – | increased appetite | anorexia | – |
mental disorders | – | decrease in mood | depression, mental disorders, insomnia, sleep disorders, aggression. | mood change, decreased libido, increased libido. |
nervous system | headache | dizziness, migraine. | ischemic stroke, cerebrovascular disorders, dystonia. | – |
the organ of vision | – | – | dryness of the mucous membrane of the eyes, irritation of the mucous membrane of the eyes, oscillopsia, visual impairment. | intolerance to contact lenses |
the organ of hearing and labyrinth disorders | – | – | sudden hearing loss, tinnitus, dizziness, hearing loss. | – |
cardiovascular system | – | increased blood pressure, decrease blood pressure. | cardiovascular disorders, tachycardia, venous and arterial thromboembolic complications, thrombophlebitis, diastolic hypertension, orthostatic circulatory dystonia, “hot flashes”, varicose veins, venous pathology, pain in the veins. | – |
respiratory system | – | – | bronchial asthma, hyperventilation. | – |
gastrointestinal tract | – | abdominal pain, including pain in the upper and lower abdomen, discomfort / bloating, nausea, vomiting, diarrhea. | gastritis, enteritis, dyspepsia. | – |
skin and subcutaneous tissues | – | acne, alopecia, rash (including macular rash), pruritus (including generalized pruritus). |
allergic dermatitis, atopic dermatitis/neurodermatitis, eczema, psoriasis, hyperhidrosis, chloasma, pigmentation disorders/hyperpigmentation, seborrhea, dandruff, hirsutism, skin pathology, skin reactions, orange peel, spider veins. | urticaria, erythema nodosum, erythema multiforme. |
musculoskeletal system | – | – | back pain, discomfort in the muscles and skeleton, myalgia, pain in the limbs. | – |
genitals and mammary glands | pain in the mammary gland, discomfort, tenderness of the mammary glands. | changes in the volume, duration and interval of menstrual bleeding (including heavy menstrual bleeding / bleeding, discharge from the genital tract / vaginal discharge, ovarian cyst, pain in the pelvic area; rarely – cervical dysplasia, uterine appendage cysts, pain in the area appendages of the uterus, cysts of the mammary glands, fibrocystic mastopathy, dyspareunia, galactorrhea, menstrual disorders. | – | secretions from the mammary glands. |
general disorders and disorders at the injection site | – | fatigue, asthenia, feeling unwell. | chest pain, peripheral edema, flu-like symptoms, inflammation, fever, irritability | fluid retention |
impact on the results of laboratory and instrumental studies | – | changes in body weight | an increase in the concentration of triglycerides in the blood, hypercholesterolemia. | – |
Interactions
If you take the drugs inducing hepatic microsomal enzymes and birth control pills including Tarina Fe 1 / 20 there observed the clearance of sex hormones. Such an increase provokes breakthrough bleeding together with the decrease in the contraceptive effect.
There is an increase in the clearance of the active substances of Tarina Fe 1 / 20 if taken together with: phenytoin, barbiturates, bosentan, primidone, carbamazepine, rifampicin and HIV treatment agents (ritonavir, nevirapine and efavirenz) and, possibly, oxcarbazepine, topiramate, felbamate, griseofulvin, as well as preparations containing St. John’s wort.
Many HIV protease or hepatitis C virus inhibitors and non-nucleoside reverse transcriptase inhibitors taken together with the combination norethindrone and etinyl estradiol can either increase or decrease the estrogen or progestin rate in the blood plasma.
What if I miss a dose?
Missing a placebo pill has no effect on the contraceptive reliability.
However, such missed placebo pills should be thrown away not to prolong this birth control phase. The recommendations given below are related only to missing of pills containing hormones. If a woman forgets to take the pill for less than 24 hours, there will no effect on the contraceptive reliability. A woman should apply this pill as fast as possible and continue the regimen as it was.
If a woman forgets to take the pill for more than 24 hours, there is an abrupt decrease in the contraceptive reliability. The more missed pills and the closer the pills to the inactive placebo stage is, the chance to become pregnant is higher.
Tarina Fe 1/20 and pregnancy
Tarina Fe 1/20 is contraindicated during pregnancy. If a woman plans to have a baby, she is able to discontinue birth control at any time. If pregnancy is established at the moment a woman takes this drug it should be withdrawn immediately. However, there were conducted extensive epidemiological studies which have not revealed any aggravated risk of developmental dysfunctions in children born by women who took combined oral contraceptives before pregnancy, or to a teratogenic effect, when such medications’ withdrawal was neglected in the early stages of pregnancy.
The existing data on the outcomes of applying the drug during pregnancy is constricted. It does not allow to make any considerations about the drug effect on the course of pregnancy, the health of the newborn and the fetus.
Breastfeeding and Tarina Fe 1/20
Use of Tarina Fe 1/20 during breastfeeding is contraindicated as well. Taking combined contraceptives can decrease the volume of breast milk making the changes in its composition. Until breastfeeding is arrested it is necessary to withdraw the medication. A small amount of hormones and/or their metabolites can become a part of breast milk damaging the body of the newborn.